4th Annual

Global Pharmacovigilance

and Risk Management

Summit

6th - 8th October 2020, Online

2 DAYS CONFERENCE + 1 DAY WORKSHOP
Attendees
+
Case Studies
+
Top companies
+
speakers
+

Some Of Our Keynote Speakers

“get inspired from the world’s leading experts”

0

Mircea CIUCA

Global Therapeutic Area Head - Global Clinical Safety and Pharmacovigilance

Jan STENBERG

Medical Director, Biosimilars in Nordic & CEE regions

Marion Wolf
Marion WOLF

Head | Senior Director Risk Management & Central Monitoring

Phillip EICHORN_

Phillip EICHORN

Senior Director, Business Management, Medical & Safety

Andreas Osanger

Andreas OSANGER

Director-Therapeutic Area Lead Nephrology

0

Colleen WALSH

Senior Director, PV and Regulatory Quality Management Operations

GLOBAL (12)

Salvatore CICIRELLO

Sr Director Pharmacovigilance Innovation, Global Drug Safety & Risk Management

Dimitris_Zampatis2

Dr Dimitris ZAMPATIS

Associate Director Signal and Risk Management Process

Some of Their Case Studies

Case Study

Day 2

Jan STENBERG

Medical Director, Biosimilars in
Nordic & CEE regions

Biogen

Nocebo impact of PV reporting in Real World practice

  • Nocebo difference impact in real World practice vs Randomized controlled
    Trials
  • Nocebo/Placebo impact of originator vs generic/Biosimilar products safety
    reporting.
  • Several practical experience where Nocebo play an important role in
    safety/PV reporting from some of my 10 countries; (at least Iceland, Norway, Denmark and Czech)
  • Some innovative ideas on how to approach this topic in the future from a PVperspective

Case Study

Day 1

​​Andreas OSANGER

Director-Therapeutic Area Lead Nephrology

Vifor Pharma

PV best practices in 2020 and beyond: Putting a patient-centric cross-functional safety strategy in the focus!

  • What we can do to increase the value of pharmacovigilance in pharmaceutical organisations?
  • How drug safety will take a more pro-active role in medicines’ life-cycles?
  • Why we shall set up safety strategy frameworks?
  • How we are able to leverage cross-functional Benefit-Risk Management Teams?
  •  

Case Study

Day 1

Salvatore CICIRELLO

Sr Director Pharmacovigilance Innovation, Global Drug Safety & Risk Management

Celgene

Informatics technologies in Pharmacovigilance: adoption of AI and
Machine learning and the role of the Drug Safety Professional

  • A framework model for leveraging PV innovation
  • Development of cognitive services
  • How the PV tech revolution will affect role of the drug safety professional

Silver Sponsor

ProPharma Group is an industry leader providing life science consulting, medical information, pharmacovigilance, and regulatory affairs services to the pharmaceutical, biotechnology, and medical device industries.

We enable clients to deliver their products to patients in the most safe, compliant, and timely manner possible. Backed by years of experience, our highly trained team understands the needs companies have in this heavily regulated environment. ProPharma Group’s experts custom tailor solutions for each of our clients based upon their unique needs and goals.

By creating an integrated compliance solution, ProPharma Group is your global, single source for the insights and services needed to maintain the highest level of value and patient safety throughout the product lifecycle. We are headquartered in Overland Park, Kansas with offices across the country, and around the world.


WHAT SOME OF OUR ATTENDEES HAVE TO SAY​